Next-IO™ Anti-Amyloid-β Monoclonal Antibody Program

Creative Biolabs has launched a series of Next-IO™ programs to bring new medicines to the world. We are dedicated to being the trusted partner of drug discovery, development, and manufacturing. By building strong, productive relationships with our partners, we are confident to achieve their scientific and business goals that exceed expectations. This program aims to develop monoclonal therapeutic antibody (mAb) targeting amyloid-β that plays a critical role in Alzheimer's Disease.

Learn more: Next-IO™ Anti-Amyloid-β Monoclonal Antibody Program